This bill establishes a National Biopharmaceutical Manufacturing Center of Excellence to advance how the United States develops and produces medicines using biotechnology. The center will be operated by a selected university, nonprofit, or public-private partnership and will focus on improving manufacturing processes, supporting workforce training, and reducing reliance on foreign supply chains for critical biopharmaceutical products. The bill directs the National Institute of Standards and Technology to award a competitive grant or contract within 180 days to establish the center, which will work with federal agencies, educational institutions, and private companies to develop innovative manufacturing technologies and practices. Congress has authorized $120 million in funding for fiscal year 2026 to support the center's construction, research, and operations, with progress reports required at regular intervals over the first five years of operation.
Take Action
Your position
Add a comment
to comment on this bill.
Annotate the text
Highlight any passage on the Summary or Full Text tab to attach a note. Annotations appear on the Annotations tab.